Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3819839 | 0.82 | SRC (0.37) | — | |
| SCHEMBL840411 | 0.80 | RXRA (0.33) | ALDH1A1 | |
| SCHEMBL3817420 | 0.80 | EGLN2 (0.33) | ALDH1A1 | |
| SCHEMBL1395973 | 0.79 | NOS3 (0.34) | ALDH1A1 | |
| SCHEMBL28111316 | 0.77 | — | — | |
| SCHEMBL28550161 | 0.77 | ACHE (0.35) | MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL28520870 | 0.72 | ANPEP (0.30) | — | |
| SCHEMBL7728424 | 0.72 | LMNA (0.32) | — | |
| SCHEMBL22421482 | 0.71 | RAPGEF4 (0.41) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL25767798 | 0.70 | LMNA (0.35) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150045558-A1 | RUTHENIUM-BASED METATHESIS CATALYSTS AND PRECURSORS FOR THEIR PREPARATION | UMICORE AG & CO. KG (DE) | 2015-02-12 | — | — | US | claimed |
| US-6403802-B1 | MIXING IN LIQUID MEDIUM STRONG BASE, ARYL HALIDE OR ARYL PSEUDOHALIDE, PRIMARY AND/OR SECONDARY AMINE, NICKEL, PALLADIUM OR PLATINUM COMPOUND, N-HETEROCYCLIC CARBENE SUCH AS IMIDAZOLINE-2-YLIDENE, BIS(IMIDAZOLINE-2-YLIDENE) OR SALTS | UNIVERSITY OF NEW ORLEANS RESEARCH & TECHNOLOGY FOUNDATION | 2002-06-11 | — | — | US | disclosed |
| WO-2001066248-A2 | C-C AND C-N COUPLING CATALYST COMPRISING TRANSITION METAL AND CARBENE | UNIVERSITY OF NEW ORLEANS RESEARCH AND TECHNOLOGY FOUNDATION (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045558-A1 | RUTHENIUM-BASED METATHESIS CATALYSTS AND PRECURSORS FOR THEIR PREPARATION | HMBS, RNF168, RRP12 | MEN1 2612/4885ALDH1A1 1435/4885MAPT 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.